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Although safety proﬁles of sirolimus-eluting stents do not seem to diﬀer in short-to-medium term from those of bare-metal
stents, late stent thrombosis after deployment of drug-eluting stents has emerged as a potential safety concern in the era of high-
pressure stent implantation. Here, we describe the case of a patient with acute myocardial infarction due to stent thrombosis
of a sirolimus-eluting stent 42 months after stent deployment and 5 weeks after discontinuation of aspirin treatment. To the
best of our knowledge, this is one of the most delayed cases of sirolimus-eluting stent thrombosis described so far. The case
emphasizes the potential risk that late stent thrombosis can unpredictably occur at any time point after drug-eluting stent
deployment.
Copyright © 2009 Dirk Sibbing et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Stent thrombosis following percutaneous coronary interven-
tion (PCI) is regarded as a complication of the procedure
mainly occurring during the ﬁrst 30 postprocedural days.
However, concerns have been raised that late stent thrombo-
sis (>30 days after PCI)—basically due to delayed endothe-
lialization of the stent struts—may be a potential limitation
following deployment of drug-eluting stents (DESs) [1].
Premature discontinuation of antiplatelet treatment was
identiﬁed as the most important independent predictor
of stent thrombosis after successful DES implantation [1].
Recently, data are accumulating that late or very late (>1y e a r
after PCI) stent thrombosis can unpredictably occur at any
time point after DES deployment [2–5]. In this case report,
we describe a patient with acute myocardial infarction due
to stent thrombosis of a sirolimus-eluting stent 42 months
after stent deployment and 5 weeks after discontinuation of
aspirin treatment.
2. Case Presentation
A 72-year-old man with a known history of coronary artery
disease (CAD) was admitted to our cardiology department
in September 2006 with symptoms of acute and ongoing
chest pain at rest. 42 months before this admission, in March
2003, coronary angiography showed a two-vessel coronary
disease with two signiﬁcant lesions of the left circumﬂex
(LCx) artery. One sirolimus-eluting stent (Cypher, 3mm
diameter, 13mm long; Cordis, Miami Lakes, Fla, USA) was
placed in the 1st left posterolateral branch and a second
bare-metal stent (BeStent, 2.5mm diameter, 12mm long,
Medtronic, Minneapolis, Minn, USA) was implanted in the
2nd left posterolateral branch of the LCx. The patient was
discharged on dual antithrombotic medication consisting
of aspirin and clopidogrel. In September 2003, 6 months
after PCI, coronary angiography demonstrated both a patent
bare-metal and sirolimus-eluting stents. Clopidogrel was





Figure 1: (a) Coronary angiography showing a total occlusion
of the 1st left posterolateral branch of the left circumﬂex artery
(see arrow), an ostial stenosis (see arrow head) of the 2nd left
posterolateral branch (proximal to the bare-metal stent), and a
patent bare-metal BeStent (see asterisk). (b) Coronary angiography
demonstrating stent occlusion of sirolimus-eluting stent and exten-
sive thrombus after guidewire passage (see arrow). (c) Coronary
angiography documenting vessel patency after balloon angioplasty.
was on monotherapy with aspirin 200mg/d. The following
three years were uneventful regarding his CAD. At the end
of July 2006, 5 weeks before his present admission, aspirin
was discontinued due to planned dental surgery and planned
coloscopy with a potential demand for polypectomy. On
his present admission, emergency coronary angiography was
performed due to ongoing chest pain, a positive troponin
T (0.21ng/mL) and an elevated level (350IU/L) of creatine
kinase (CK). Angiography showed total occlusion of the
1st left posterolateral branch, an ostial stenosis of the 2nd
left posterolateral branch (proximal to the bare-metal stent)
and a patent bare-metal BeStent (Figure 1(a)). Further on,
angiography demonstrated stent occlusion of sirolimus-
eluting stent and extensive thrombus after guidewire passage
(Figure 1(b)). Ballon angioplasty was successful and restored
vessel patency (Figure 1(c)); peak concentration of CK was
2116 IU/L.
3. Discussion
To the best of our knowledge, this is one of the most delayed
cases of sirolimus-eluting stent thrombosis described so far.
Late-stent thrombosis, 42 months after deployment, was
probably due to aspirin withdrawal accompanied by a lack
of endothelialization of the stent struts. A second possible
and previously reported mechanism could be persistent
and extensive inﬂammatory reaction of the arterial wall
surrounding the stent as a reaction to the polymer [6]. The
case emphasizes the potential risk that late stent thrombosis
can unpredictably occur at any time point after drug-
eluting stent deployment [7]. Stent thrombosis must be
considered as a potential risk when discontinuation of
antiplatelet medication is contemplated and any decision
to stop antiplatelet therapy for whatever reason in patients
exhibiting drug-eluting stents should take this into account.
Moreover, this case and others raise questions about current
recommendations for the duration and indications to dis-
continue antiplatelet therapy after DES implantation.
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